Reducing Zoledronic Acid Frequency Did Not Raise Risk of Skeletal Events

Among cancer patients with bone metastases, administration of zoledronic acid every 12 weeks did not increase the risk of skeletal events over 2 years compared with the standard dosing of every 4 weeks.

Source: CancerNetwork - January 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bone Metastases Breast Cancer Multiple Myeloma News Prostate Cancer Source Type: news